Exicure is developing nucleic acid therapies that target ribonucleic acid targets linked to neurological disorders and hair loss. To develop next-generation nucleic acid therapeutics Exicure is using their proprietary spherical nucleic acid (SNATM) platform. SNAs have a unique chemical structure with synthetic nucleic acid sequences densely radiating from a spherical core. This structure offers advantages over other nucleic acid technologies including unparalleled transfection efficiency into numerous cell and tissue types and multi-targeting capabilities. Exicure’s refined discovery and development process has led them to identify several promising candidates in CNS conditions quickly.

Exicure

Founded: 2011
Location: Chicago, IL
Employee range: 11 - 50
Clinical stage: Clin0
Therapy area: Neuropathic pain
Drug types: NEU, PN
Lead product: SCN9A
Funding: $11.5M stock Dec 2021; $27.5M IPO Dec 2019; $13.6M C Jun 2014

Drug notes:

About:

Jobs: